Compare Novavax Inc (NVAX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Wendys Co — how do they compare? Novavax Inc trades at $9.85 (market cap $1.62B), while Wendys Co trades at $7.55 (market cap $1.44B). The key difference: Novavax Inc and Wendys Co are close in size by market cap, and Wendys Co pays a 3.71% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WEN | |
|---|---|---|
Market Cap | $1.62B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $9.89 |
52-Week Low | $6.22 | $6.17 |
Enterprise Value | $1.20B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Wendy's (WEN) trades at $7.61, down 5.23% on the day, reflecting bearish technical signals and negative sentiment following the collapse of Trian's potential take-private bid. The stock shows a low P/E of 11.54 and P/S of 0.66, indicating potential undervaluation, but faces declining net income margins and high debt levels. Recent earnings have consistently beaten expectations, yet U.S. traffic fell 12.5% in 2026, highlighting operational challenges under new CEO Bob Wright's turnaround plan.
The outlook is cautious; while valuation metrics appear attractive and analyst consensus targets $8.13, near-term risks from weak sales, high leverage, and failed M&A speculation outweigh opportunities. Investors should monitor execution of the five-point reset strategy for traffic recovery, but competitive pressures and inconsistent cash flow generation pose significant headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
